Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
Corcept reported positive results from Part A of the Phase 2 BELLA trial, with Lifyorli (relacorilant) plus nab-paclitaxel and bevacizumab delivering a median PFS of 7.2 months and ORR of 59% in 95 patients with platinum-resistant ovarian cancer. For comparison, the pivotal Phase 3 ROSELLA study showed median PFS of 5.4 months and ORR of 37% for Lifyorli plus nab-paclitaxel, versus 3.9 months and 30% for nab-paclitaxel alone. Benefit was most pronounced in bevacizumab-naive patients, with median PFS of 8.1 months, ORR of 66% and 6-month OS of 91%. No new safety signals were identified.
Key figures
- Drug Name
- Lifyorli (relacorilant)
- Phase Of Trial
- Phase 2
- Orr triplet
- 59%
- Trial sites
- approximately 45
- Os 6month triplet
- 88%
- Patients enrolled
- 95
- Median pfs triplet
- 7.2 months
- Orr bevacizumab naive
- 66%
- Orr nabpaclitaxel alone
- 30%
- Orr lifyorli nabpaclitaxel
- 37%
- Os 6month bevacizumab naive
- 91%
- Median pfs bevacizumab naive
- 8.1 months
- Median pfs nabpaclitaxel alone
- 3.9 months
- Median pfs lifyorli nabpaclitaxel
- 5.4 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.